We aimed to elucidate the relation between serum uric acid (SUA) level and severity of coronary artery disease (CAD) in nondiabetic, nonhypertensive patients (n = 246) with acute coronary syndrome (ACS). Severity of CAD was assessed by the Gensini score. One, 2, and 3 or more diseased vessels were identified in 87 (35.4%), 55 (22.4%), and 104 (42.2%) patients, respectively. Patients with hyperuricemia had higher Gensini score, high number of diseased vessels, critical lesions, and total occlusion. Serum uric acid level was significantly associated with number of diseased vessels. Serum uric acid was an independent risk factor for multivessel disease by univariate analysis. High levels of SUA associated with the severity of CAD in nondiabetic, nonhypertensive patients with ACS.
OkuraTHigakiJKurataM. Japanese coronary artery disease study investigators. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J. 2009;73(5):885–891.
2.
MeisingerCKoenigWBaumertJDöringA. Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population. The MONICA/KORA cohort study. Arterioscler Thromb Vasc Biol. 2008;28(6):1186–1192.
3.
KaragiannisAMikhailidisDPTziomalosK. Serum uric acid as an independent predictor of early death after acute stroke. Circ J. 2007;71(7):1120–1127.
4.
HøieggenAAldermanMHKjeldsenSE. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041–1049.
5.
Vasquez-VivarJSantosAMJunqueiraVBAugustoO. Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acidderived free radicals. Biochem J. 1996;314(pt 3):869–876.
6.
AnkerSDLeyvaFPoole-WilsonPAKoxWJStevensonJCCoatsAJ. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart. 1997;78(1):39–43.
7.
NaghaviMJohnRNaguibS. pH heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis. 2002;164(1):27–35.
GensiniGG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606–607.
10.
KanellisJWatanabeSLiJH. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287–1293.
11.
KrishnanEPandyaBJChungLDabbousO. Hyperuricemia and the risk for subclinical coronary atherosclerosis—data from a prospective observational cohort study. Arthritis Res Ther. 2011;13(2):R66.
12.
ChenJHChuangSYChenHJYehWTPanWH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61(2):225–232.
13.
KimSYGuevaraJPKimKMChoiHKHeitjanDFAlbertDA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62(2):170–180.
14.
WaringWSAdwaniSHBreukelsOWebbDJMaxwellSR. Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart. 2004;90(2):155–159.
15.
TsaiTHChenYLChenSM. Uric acid is not an independent predictor of cardiovascular death in patients with angiographically proven coronary artery disease. Chang Gung Med J. 2009;32(6):605–613.
16.
GagliardiACMinameMHSantosRD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202(1):11–17.
17.
KanellisJKangDH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25(1):39–42.
18.
JohnsonRKangDFeigD. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?Hypertension. 2003;41(6):1183–1189.
19.
KanbayMSánchez-LosadaLGFrancoM. Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant. 2011;26(2):430–437.
20.
DawsonJWaltersM. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?Br J Clin Pharmacol. 2006;62(6):633–644.
21.
TavilYKayaMGOktarSO. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis. 2008;197:159–163.
22.
FeigDIKangDHJohnsonRJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821.
23.
NiskanenLLaaksonenDELindstromJ. Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish diabetes prevention study. Diabetes Care. 2006;29(3):709–711.
24.
DeveciOSKabakciGOkutucuS. The association between serum uric acid level and coronary artery disease. Int J Clin Pract. 2010;64(7):900–907.
25.
KanbayMIkizekMSolakY. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol. 2011;33(4):325–331.
26.
LuPHuDLuJWangWChenB. The association between uric acid and coronary heart disease. Zhonghua Nei Ke Za Zhi. 2002;41(8):526–529.
27.
GurMYilmazRDemirbagRAksoyN. Relation of serum uric acid levels with the presence and severity of angiographic coronary artery disease. Angiology. 2008;59(2):166–171.
28.
DaskalopoulouSSTzovarasVMikhailidisDPElisafM. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des. 2005;11(32):4161–4175.
29.
Jelic-IvanicZMemonLSpasojevic-KalimanovskaVBogavac-StanojevicNSpasicS. Independent association of high serum uric acid concentration with angiographically defined coronary artery disease. Tohoku J Exp Med. 2007;211(4):369–377.
30.
VaziriNDFreelRKHatchM. Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol. 1995;6(4):1313–1317.
31.
AthyrosVGKaragiannisAGanotakisES. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin. 2011;27(8):1659–1668.
32.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): a relationship with implications for vascular risk?Curr Vasc Pharmacol. 2011 Sep 22;9(6):698–705.
33.
StrasakARuttmannEBrantL. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian men. Clin Chem. 2008;54(2):273–284.
34.
SerruysPWOnumaYGargS. Assessment of the SYNTAX score in the syntax study. EuroIntervention. 2009;5(1):50–56.
35.
AthyrosVGMikhailidisDPLiberopoulosEN. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007;22(1):118–127.
